Li, Yulin
Thomas, Daniel
Deutzmann, Anja
Majeti, Ravindra
Felsher, Dean W.
Dill, David L.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K22CA207598, R01CA188055, U54CA143907, U54CA149145)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 20 June 2019
Accepted: 30 October 2019
First Online: 14 November 2019
Competing interests
: This work was supported in part by: NCI K22CA207598 (Y.L.), NIH U54CA149145 (D.L.D. and D.W.F.), NIH U54CA143907 (D.W.F. and Y.L.), NIH R01CA188055 (R.M.), an Australian National Health and Medical Research Council Overseas Biomedical Research Fellowship (D.T.), a postdoctoral fellowship from Lymphoma Research Foundation (A.D.), and a Leukemia and Lymphoma Society Scholar Award (R.M.). R.M. is a founder, consultant, equity holder, and serves on the Board of Directors of Forty Seven Inc.